Targeting Cytokines in GVHD Therapy

Sandeep Kumar1,2, Hemn Mohammadpour1, and Xuefang Cao1,*
1Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

Abstract

Transplantation of donor-derived allogeneic hematopoietic cells causes increased survival in patients suffering from various blood cancers and other hematologic and immunologic diseases. However, this health benefit is limited to certain patients. One major complication is graft-versus-host disease (GVHD) that occurs when donor-derived immune cells recognize host cells/tissues as foreign and perpetrate subsequent destruction. Cytokines are a major class of effector molecules that are involved in GVHD pathogenesis. Proinflammatory cytokines released by activated immune cells including T cells lead to the onset of GVHD. T cell depletion (TCD) is an effective approach for GVHD prevention. Several immune suppressive drugs are also used to treat GVHD. However, these prophylactic and treatment strategies often lead to an immune compromised state that increases the risk for infection and cancer relapse. Considering the adverse effects of TCD and overall immune suppression, more selective managements such as approaches targeting proinflammatory cytokines have emerged as a promising strategy to control GVHD. Therefore, this work is dedicated to review recent development in the studies of cytokines and their future implication in GVHD therapy.

Keywords

Hematopoietic cell transplantation; Graft-versus-host disease; T cells; Cytokines

INTRODUCTION

Graft-versus-host disease (GVHD) is serious complication after allogeneic hematopoietic cell transplantation (Allo-HCT). During analo-HCT procedure, hematopoietic cells harvested from an allogeneic donor are transplanted into a patient who suffers a certain type of hematologic malignancy or other hematologic or immunologic disease. After transplantation, however, donor derived immune cells may recognize normal host cells/tissues as foreign and subsequently cause tissue damages leading to onset of GVHD. The common symptoms of acute GVHD include weight loss, alopecia (hair loss on scalp and elsewhere on body), skin lesions, gastro-intestinal (GI) tract and liver complications that
may lead to death [1]. Among various cellular immune components, T cells are crucially important in the pathogenesis of GVHD. Donor T cells undergo activation, proliferation and migration into target organs as a cascade of molecular events involving interaction between T cell receptors (TCR) and major histocompatibility complex (MHC) bound allo-antigens, co-stimulatory signaling and cytokine signaling. Cytokines are immune effectors as well as regulators of various immunologic conditions including inflammation and hypersensitivity reactions [2,3]. Many studies have demonstrated that cytokines are involved in various inflammatory and regulatory activities during GVHD [4,5]. Following encounters between donor T cells and host antigen presenting cells (APCs) presenting allo-antigens, allo-reactive donor T cells are activated and undergo vigorous proliferation and then migrate to the target organs and tissues. These events are accompanied with enhanced secretion of proinflammatory cytokines that contribute to severe acute GVHD. That is why a rapid onset of acute GVHD is considered as a result of “cytokine storm” [6]. The manifestation and severity of GVHD ascribe to naïve T cells maturing and differentiating into different lineages and phenotypes including regulatory T cells (Treg), Th1, Th2, and Th17 cells (Figure 1). This differentiation is associated with the presence of local cytokines that activate transcription factors and determine supremacy of certain phenotypes [7]. Th1 cells secrete several cytokines namely interleukin-2 (IL-2), IL-10, interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and TNF-β. Th2 cells secret cytokines like IL-3, IL-4, IL-5, IL-10, IL-13, IL-17E and IL-31. Th17 is known to secrets IL-17 mainly [7]. In GVHD, donor naïve CD4+ T cells recognize allo-antigens presented on the host’s APCs and differentiated into Th1, Th2, and Th17 cells depending upon local cytokine milieus.

In MHC-mismatched models of GVHD, T helper (Th) cells differentiated into Th1 subtypes that mediate tissue damage in GI tract and liver. In the absence of IFN-γ, Th cells differentiated into Th2 and Th17 subsets and caused damage in lung and skin. If there is neither IL-4 nor IFN-γ the dominating subset is Th17 cells that lead to tissue damage in skin. If both the IFN-γ and IL-17 are absent, the dominating subset is Th2 cells that cause idiopathic pneumonia in GVHD patients [8]. Furthermore, in the presence of IL-12 Th cells differentiate into Th1 phenotype and cause release of IFN-γ and IL-2 cytokines [9]. In summary, the literature has described cytokines as effector molecules as well as regulatory factors in GVHD pathogenesis. This review aims to corroborate the past and current knowledge regarding the functions of cytokines in GVHD pathogenesis with special emphasis on potential therapeutic managements.

Th1 Cytokines in GVHD

Among various Th1 cytokines, IL-2 is one of the most studied cytokines for its role in activation, proliferation and expansion of T cells in GVHD. Several studies indicate a potential role of IL-2 in GVHD [10–14]. The role of IL-2 in GVHD is very diverse that includes amplification of allogeneic immune response, activation of T cells and NK cells, stimulating secretion of TNF-α by macrophages and inflammatory damages to the skin and gut [15]. Considering the importance of IL-2, high dose and low dose of IL-2 therapy are used to diminish GVHD [11,12]. Administration of high dose IL-2 for several days beginning on the day of allo-HCT attenuates GVHD mortality in lethally irradiated mice [11]. Low dose therapy with IL-2 has also been reported, that expands Treg population in
vivo and is associated with a lower incidence of GVHD [12]. Low dose of IL-2 restores CD4+Foxp3+Treg homeostasis without causing any adverse effect on the graft-versus-leukemia/lymphoma (GVL) response [13]. On the other hand, prevalence of chronic GVHD is characterized by constitutive phosphorylation of Stat5 in conventional CD4+ T cells (Tcons) associated with elevated amounts of IL-7 and IL-15 and relative functional deficiency of IL-2. The IL-2 therapy resulted in the selective increase of Stat5 phosphorylation in Treg and a decrease of phosphorylated Stat5 in Tcons [14]. However, there are certain limitations of IL-2 therapy in GVHD. For examples, in experimental GVHD model, IL-2 administration to donor mice induces a dose-dependent expansion of Treg cells in the graft but is insufficient to suppress GVHD [16]. In xenogeneic model of GVHD where human peripheral blood mononuclear cell transplanted into immunodeficient mice, although, low-dose IL-2 administration caused increase in Treg cells but was unable to control pro-inflammatory cytokines production by pathogenic Tcons [16]. Taken together, studies are divided into pro- and anti-IL2 therapy in GVHD.

Another member of Th1 secreted cytokines, IL-10 (also known as human cytokine synthesis inhibitory factor) is a regulatory cytokine that play an important role in GVHD. IL-10 can modulate CD4+ T cells functions by down-regulation of another Th1 cytokine IL-2 [17]. IL-10 does not contribute to GVHD mediated by effector T cells. In contrast, IL-10 creates tolerogenic environment to allo-antigens independent of IL-2 or CD28 stimulation [18]. A study, using IL-10 deficient donor or host mice in a MHC-mismatched model of acute GVHD, reported increased GVHD if either donor or host B cells were unable to produce IL-10 [19]. The induction of IL-10 release in host B cells attenuates acute GVHD in experimental model [20]. Furthermore, donor bone marrow graft and Treg-derived IL-10 are important for the donor Treg-mediated suppression of GVHD [21]. High frequency of donor cells producing IL-10 in response to host allo-antigen stimulation has been correlated with the absence of acute GVHD post allo-HCT. Conversely, low frequency of IL-10 response is strongly associated with more severe GVHD [22].

Another major Th1 cytokine, IL-12, produced mainly by dendritic cells and macrophages, is a heterodimeric cytokine that mediated cellular immunity [23]. The dimeric components of IL-12 are a heavy chain subunit p40 and a light chain subunit p35 that are critical for the functions of active IL-12 [23]. Interestingly, IL-12 shares a common p40 subunit with another cytokine IL-23. This subunit is important for driving Th1 differentiation and stabilization of Th17 phenotype. Result showed that both donor- and host-derived p40 is important for the induction of acute GVHD. The therapeutic efficacy of anti-p40 was evident by its ability to reduce acute GVHD [24].

Pro-inflammatory cytokine IFN-γ is mainly produced by activated T-cells, NKT cells and NK cells. IFN-γ inhibits GVHD in lethally irradiated mice receiving allo-HCT but promotes lethality in un-irradiated and sub-lethally irradiated recipients [25]. The extent of conditioning markedly affects the role of IFN-γ in GVHD lesions mediated by CD4+ T cells. For example, in a GVHD model using sub-lethal total body irradiation (TBI), the absence of IFN-γ is playing a protective role in GVHD, while in lethal TBI1 condition, loss of IFN-γ is associated with increased pathogenesis [26]. However, there is experimental evidence that IFN-γ may not be required in GVHD pathogenesis but can facilitate the GVL.
effects [27]. Further studies are required to explore IFN-γ involvement in GVHD for more in depth insight on its use as a therapeutic target.

Another cytokine from Th1 family that plays important role in the GVHD is TNF-α. It is directly involved in tissue damages by inducing apoptosis or necrosis of target cells and synergizes with cytotoxic T lymphocytes and NK cells [28]. Therefore, use of TNF-α antagonist has shown promising results in GVHD management. For example, Korngold et al., have investigated that the inhibition of TNF-α during HCT can diminish inflammatory GVHD reactions without hindering effective GVL response [28]. However, a recent study reported that TNF-α priming can enhance CD4+ Foxp3+ regulatory cell suppressive function to attenuates GVHD [29]. Also, another study indicated that GVHD control depends to production of TNF-α by T cells and expression of TNFR2 on regulatory T cells [30].

In summary, the roles of Th1 cytokines in GVHD pathogenesis are diverse yet not completely defined. Management of Th1 cytokines for GVHD prophylaxis and treatment appears promising, but optimization is still an issue that needs further effort.

**Th2 Cytokines in GVHD**

Th2 cytokines can attenuate Th1 cytokines such as TNF-α and interrupt Th1 cytokine cascade post allo-HCT and therefore was once thought to lead to the suppression of GVHD pathogenesis [31]. Recently, transplantation of myeloid derived suppressor cells (MDSCs) has been reported to skew allogeneic T cell response toward Th2 cells and enhanced Th2-specific cytokines that caused suppressed GVHD [32]. However, other studies have suggested various cytokines of Th2 family are associated with GVHD. For example, IL-3 is a growth promoting cytokine involved in the differentiation and apoptosis of various hematopoietic cell types [33]. Up-regulated level of IL-3 is reported in a significant subgroup of patients suffering from extensive chronic GVHD [34]. Similarly, high-dosage of IL-3 accelerates GVHD and impairs survival of the host [35]. Another Th2 cytokine, IL-4 is a pleiotropic cytokine produced by activated T cells [36]. The IL-4 receptor (IL-4R) also binds to IL-13, that contribute to several overlapping functions of IL-4 and IL-13 [37]. IL-4 plays an important role in the regulation or pathogenesis of allogeneic responses [38]. Th2 cell therapy can rapidly ameliorate severe GVHD by creating hindrance in IL-4 and IL-10 functions, IL-2 consumption and APC modulation [39]. IL-5 is another member of Th2 cytokine family originally defined as a T-cell-derived cytokine that triggers activated B cells for terminal differentiation into antibody-secreting plasma cells at least in mice [40]. Elevated level of serum IL-5 is reported in acute GVHD [41]. The cytokines IL-5, IFN-γ, and TNF-α have been used as biomarkers of acute GVHD [42]. IL-13 is mainly involved in the allergic inflammation and other ailments including GVHD [3]. Therefore, association between IL-13 levels and acute GVHD may be exploited as a strong predictor of this disease. In summary, it is now clear that acute GVHD is not a purely Th1-type cytokine-driven response, but Th2-type cytokine such as IL-13 has also been involved in the pathogenesis of acute GVHD [42]. Therefore, the roles of these Th2 cytokines need further mechanistic clarification in GVHD pathogenesis and management to achieve optimum exploitation.
Th17 Cytokines in GVHD

Th17 cells are known to release cytokines including IL-17 and IL-22 [43]. Th17 cells synergize with naive T cells to induce lethal GVHD. In vitro polarized Th17 cells can induce higher GVHD leading to the severe skin and pulmonary conditions [44]. Th17 cells have an inverse relationship with Treg cells in GVHD. The dynamic changes of Th17 and Treg cells along with the level of Th17 cytokines are associated with the onset and resolution of acute GVHD [43]. IL-17 mediates its function via surface receptors on target cells [45]. Participation of IL-17 has been studied in the acute rejection of organ transplants and GVHD [46]. Both CD4+ IL-17-producing T cells and CD8+ IL17-producing T cells secrete the IL-17 cytokine. These subsets of T cells are suspected to initiate Th1 response at early phase in GVHD [47]. In an allo-HCT model using pan T cells, IL-17 is dispensable for GVHD and GVL activity. However, IL-17 contributes to the early development of CD4+ T cell-mediated GVHD by up-regulating production of proinflammatory cytokines [46]. Concurrent to this study reports IL-17-producing CD8+ T (Tc17) in the initiation of GVHD [48]. In addition to IL-17, other Th17 cytokines are also targeted by researchers to explore their role in GVHD. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to GVHD [49]. Treatment with IL-22 in vivo after allo-HCT enhanced the recovery of intestinal stem cells, increased epithelial regeneration and reduced intestinal pathology and mortality from GVHD [50]. In addition, IL-22 producing RORγt+ILC3 subset was reported to be involved in the prevention of intestinal GVHD via strengthening the intestinal mucosal barrier [51]. Furthermore, one of the other important cytokines that is produced by Th17 and T follicular helper cells is IL-21 [7]. Also, splenic neutrophils can express IL-21 during acute GVHD [52]. IL-21 was shown to play a critical role in GVHD development through increasing B cell activation and proliferation, alloantibody generation and disrupting Treg homeostasis [53,54]. It was also shown that direct or indirect (through Rho associated kinase 2) inhibition of IL-21 ameliorated GVHD symptoms [55]. Taken together, these studies show that the diverse roles of Th17 cytokines in GVHD are highly important, yet more in depth explorations are still required to define the precise contributions of various Th17 cytokines in GVHD.

Other Cytokines, Chemokines and T Cell Populations in GVHD

Apart from Th1, Th2 and Th17 cytokines, various other cytokines also play important roles in GVHD directly or indirectly. For example, TGF-β-dependent CD103 expression is involved in regulating destruction of gut epithelium by CD8+ T cells during GVHD pathogenesis [56]. The anti-inflammatory cytokine IL-35 can suppress acute GVHD in patients post allo-HCT. This cytokine targets phosphorylation of STAT1 and STAT4 which is generally inhibited in mice in acute GVHD. Treatment of IL-35 leads to up-regulated phosphorylation of STAT1 and STAT4 and amelioration of acute GVHD. These observations advocate the potential therapeutic efficacy of IL-35 in GVHD [57]. Homeostatic interleukin IL-7 regulates T cell survival and proliferation in vivo and is also known as a thymotropic cytokine along with SCF [58,59]. A recent study suggests that elevated IL-7 but not SCF is associated with development of GVHD [59]. Another proinflammatory cytokine, IL-15, induces T cell proliferation and demonstrates IL-2-like properties [60]. Both IL-7 and IL-15 have been associated with the peripheral T cells regeneration in mice and humans [61]. Considering the importance of IL-7 and IL-15 in immune functions, these cytokines have
been targeted for the treatment of acute GVHD [61]. In addition, increased levels of cytokines and chemokines including B cell activating factor (BAFF), IL-33, CXCL10 and CXCL11 are reported in GVHD pathogenesis [62]. The role of chemokine CCR7 in GVHD is especially affiliated with gastrointestinal (GI) tract complications. CCR7 significantly regulates elevated allo-antigens presentation in mesenteric lymph nodes of GI tract [63]. Furthermore, the binding of IL-33 to receptor “suppression of tumorigenicity 2 (ST2)” presents intriguingly both pro-inflammatory and anti-inflammatory effects. The increased levels of soluble ST2 are a biomarker for steroid-refractory GVHD and mortality. Blockade of IL-33 and ST2 interaction induces marked reduction in GVHD lethality [64]. Another recent study suggests a role of IL-26 in the pathogenesis of transplant-related obliterative bronchiolitis as IL-26⁺CD26⁺CD4⁺ T cells in part induces chronic GVHD of the lungs [1]. Moreover, IL-1β and associated MyD88 signaling in dendritic cells and T cells are involved in GVHD. After conditioning therapy, the microbial products and uric acid can activate NLRP-3 in donor T cells to increase IL-1β expression that subsequently enhances GVHD severity [65]. On the other hand, it has been demonstrated that MyD88 deficiency in T-cell depleted donor BM leads to attenuated GVHD symptoms [66].

In addition to Th1, Th2 and Th17 cells that produce associated cytokines and affect GVHD, there are several important T cell populations that also impact GVHD via cytokines and other mechanisms. Many studies have documented the roles of Treg cells in GVHD. Both natural and induced Treg cells are able to restrain conventional T cell proliferation and attenuate GVHD with multiple mechanisms including IL-2, IL-10 and TGF-β [67]. CD4⁺CD103⁺Fop3⁺natural Treg can directly migrate to GVHD target organs decreasing disease severity [68]. Notably, the Th17/Treg ratio is correlated with clinical and pathological GVHD and therefore could be used as a biomarker of GVHD [69]. IL-2 treatment in combination with rapamycin has been shown to mitigate acute GVHD lethality, which is associated with increased expansion of donor-type CD4⁺Foxp3⁺ Treg cells and reduction of CD4⁺CD25⁺ conventional T cells [67]. In addition, T follicular helper (Tfh) cells are responsible for naïve B cells differentiation to memory B cells and immunoglobulin class switching. Tfh cells express BCL-6 as transcription factor and CXCR5 and PD-1 surface markers with high secretion of IL-21 cytokine. Tfh cells mostly locate in germinal center but a subset of Tfh cells have been detected in peripheral blood. Tfh cells are required for generation and maintenance of germinal center and B cells function in chronic GVHD. These circulating Tfh cells appear to cause aggravation of chronic GVHD [70,71]. Furthermore, a more recent study has described a new CD4⁺ memory T population with high expression of CD11c and α4β7 in gut that plays a pivotal role in initiating gastrointestinal GVHD via promoting Th1 response and cytokine production [72].

Taken together, these studies indicate that a wide range of cytokines and T cell populations are involved in the pathogenesis of GVHD. A thorough understanding of the complex molecular and cellular networks will provide better insights for more effective GVHD management.
Updates on Cytokine-Related GVHD Management Strategies

Recent years witnessed a significant growth in findings related to the role of various cytokines in the pathogenesis and management of GVHD. Several new drugs have been used to treat GVHD based on cytokine regulation. For example, zinc supplementation was reported to be beneficial in the induction of tolerance that ameliorates Th1-dominated allogeneic immune response [73]. A recent study also advocates granzyme B (GzmB) based therapeutic approach because GzmB knockout T cells are associated with the production of prominent quantity of proinflammatory cytokines that exacerbate GVHD [74]. An in vitro study using dendritic cell (DC) culture indicated that bortezomib can inhibit the proliferation of DCs and also blocked expression of costimulatory molecules CD80 and CD86. This drug was also found to diminish IL-12 and TNF-α release in DCs following treatment of LPS [75]. Another study was carried out on valproic acid, a histone deacetylase inhibitor that also possesses anti-inflammatory effects. In MHC-mismatched transplantation mouse model, valproic acid down regulated Th1 and Th17 cell responses and cytokine production in vitro and in vivo [76]. The use cyclopentylamino carboxymethylthiazolylindole-7 (NecroX-7) is found useful in controlling GVHD in preclinical models. NecroX-7 is an inhibitor of chromatin protein high mobility group box 1 (HMGB1). NecroX-7 protects mice against lethal GVHD by reciprocal regulation of Treg/Th1 cells [77]. Erlotinib, an EGFR tyrosine kinase inhibitor ameliorates sclerodermatous GVHD. These beneficial effects were mediated by decrease in IFN-γ and IL-13 production and autoimmune B-cell activation [78]. Moreover, BET bromodomain inhibition can suppress GVHD through NF-κB regulation and decrease production of inflammatory cytokines such as IL-6, IL-12, TNF-α in DCs and IFN-γ, IL-2, IL-4 and IL-17 in activated T cells [79]. Although initial outcomes of these cytokine-related therapeutic regimens raise hopes for better treatment, further study is warranted to achieve optimum benefits.

Micro RNAs (miRs) play important roles in regulation of various immune responses such as infection, tumor, and autoimmunity [80]. Recently, the function of miR-17-92 cluster in allogeneic T cell response has been studied. Results suggest an important role for miR-17-92 in donor T cells for GVHD induction. The miR-17-92 promotes CD4+ T cell functions, Th1 differentiation, but down-regulates Th2 and inducible Treg functions [80]. In addition, miR-142 is implicated in hematopoietic functions including T cell response. In vivo deletion of miR-142 does not affect T cell development. But in vitro and multiple models of GVHD targeting miR-142 leads to attenuated T cell proliferation [81]. Recently, miR-155, known to regulate the innate immune system, is studied for its role in DC functions during GVHD. Study suggests that miR-155 deficiency in host system is associated with decreased proinflammatory cytokines and attenuated GVHD pathogenesis [82]. Moreover, an earlier study showed that expression of miR146a increased in donor T cells after transplantation and deficiency in Mir146a caused enhanced GVHD through TRAF6/TNF signaling pathway [83]. These studies suggest that genetic manipulation by targeting miRs in GVHD therapy may have beneficial impacts.

Uses agonistic antibodies have shown proved efficacy in GVHD management. Recently, αDR3, an antibody to death receptor 3 (DR3), has been investigated for its role in the management of GVHD. DR3 is mainly present on Treg cells, lymphoid tissue inducer cells

J Immunol Res Ther. Author manuscript; available in PMC 2017 August 15.
and NKT cells [84]. Studies showed that agonistic antibody αDR3 expanded CD4+FoxP3+ Treg cells population in vivo. Apart from the expansion of Treg cells, αDR3 also down-regulated proinflammatory cytokines such as IFN-γ, IL-1β, and TNF-α. Notably this GVHD alleviating effect was achieved by a single dose of αDR3 [84]. Another target aimed to alleviate GVHD is the TNF-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis. It was observed that attenuation of TWEAK/Fn14 system alleviated disease development in several models of colitis [85]. In GVHD, proinflammatory cytokine TNF play very important role in intestinal cell death. TWEAK up-regulates TNF-induced cell death. Therefore, proper understanding of Fn14 in TNF associated GVDH pathogenesis will be useful. As such, an antibody-dependent cell-mediated cytotoxicity (ADCC)-defective Fn14-blocking antibody has been utilized by researchers to attenuate GVHD successfully [85]. These studies advocate promising roles of monoclonal antibodies in GVHD management.

Cytokines also find uses as biomarkers for GVHD. For example, tear cytokine profile was found associated with systemic chronic GVHD. This finding is evident by the presence of enhanced levels of IL-2, IL-10, IL-17α, IFN-γ, IL-6, and TNF-α tear cytokines in chronic GVHD patients [86]. Recently, IL-6 and IL-9 have been studied for their potential as biomarkers in GVHD [87]. In addition to modulating T cells, recent study has also shown a potential role of cytokines in modulation of NK cells. Adoptive transfer of IL-12, IL-15 and IL-18 pre-activated NK cells showed suppression of GVHD in a mouse model of MHC-mismatched HCT [88]. Together, adoptive transfer of cytokines pretreated immune cells will pose a potential impact on the GVHD management.

**CONCLUDING REMARK**

In summary, the role of cytokines in GVHD is indispensable. Several therapeutic interventions based on targeting cytokines have already shown promising results in GVHD amelioration. As Th1, Th2 and Th17 cytokines are associated with the pathogenesis and management, exploitation of these immune mediators will produce practical approaches to combat GVHD. Further studies are required to understand the underlying mechanisms associated with the roles of cytokines in GVHD in order to achieve optimum diagnostic and therapeutic benefits.

**Acknowledgments**

This work was supported by NIH research grant # R01CA184728 (X.C.). We apologize to the authors whose studies are relevant to this subject but are not cited due to space limitation.

**Abbreviations**

- **Allo-HCT** Allogeneic Hematopoietic Cell Transplantation
- **Allo-HSCT** Allogeneic Hematopoietic Stem Cell Transplantation
- **BMT** Bone Marrow Transplantation
- **IL** Interleukin
TNF-α  Tumor Necrosis Factor Alpha
IFN-γ  Interferon Gamma
TGF  Transforming Growth Factor
GVHD  Graft-Versus-Host Disease

References

1. Ohnuma K, Hatano R, Aune TM, Otsuka H, Iwata S, et al. Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes. J Immunol. 2015; 194:3697–3712. [PubMed: 25786689]
2. Kelso A. Cytokines: principles and prospects. Immunol Cell Biol. 1998; 76:300–317. [PubMed: 9723771]
3. Kumar S, Verma AK, Das M, Dwivedi PD. Molecular mechanisms of IgE mediated food allergy. Int Immunopathol. 2012; 13:432–439. [PubMed: 22668720]
4. Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol. 1993; 5:794–799. [PubMed: 8240742]
5. Fujii N, Hiraki A, Aoe K, Murakami T, Ikeda K, et al. Serum cytokine concentrations and acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation: concurrent measurement of ten cytokines and their respective ratios using cytometric bead array. Int J Mol Med. 2006; 17:881–885. [PubMed: 16596275]
6. Mohly M, Blaise D, Faucher C, Vey N, Bouabdallah R, et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2005; 106:4407–4411. [PubMed: 16141347]
7. Henden AS, Hill GR. Cytokines in Graft-versus-Host Disease. J Immunol. 2015; 194:4604–4612. [PubMed: 25934923]
8. Yi T, Chen Y, Wang L, Du G, Huang D, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009; 114:3101–3112. [PubMed: 19602708]
9. Kichian K, Nestel FP, Kim D, Ponka P, Lapp WS. IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host-disease. Possible involvement of IFN-gamma. J Immunol. 1996; 157:2851–2856. [PubMed: 8816389]
10. Shindo T, Ishikawa T, Fukunaga A, Hori T, Uchiyama T. Growth and differentiation advantages of CD4+OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2008; 14:268–281. [PubMed: 18275893]
11. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci U S A. 1990; 87:5633–5637. [PubMed: 2377601]
12. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014; 20:2215–2225. [PubMed: 24573552]
13. Sykes M, Harty MW, Szot GL, Pearson DA. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood. 1994; 83:2560–2569. [PubMed: 7909457]
14. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013; 5:179ra143.
15. Ball LM, Egeler RM. EBMT Paediatric Working Party. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008; 41(Suppl 2):S58–64. [PubMed: 18545246]
16. Pérol L, Martin GH, Maury S, Cohen JL, Piaggio E. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease. Immunol Lett. 2014; 162:173–184. [PubMed: 25445496]

17. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood. 1993; 81:2964–2971. [PubMed: 8499633]

18. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996; 184:19–29. [PubMed: 8691133]

19. Weber M, Stein P, Prüfer S, Rudolph B, Kreft A, et al. Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease. Eur J Immunol. 2014; 44:1857–1865. [PubMed: 24637445]

20. Rowe V, Banovic T, MacDonald KP, Kuns R, Don AL, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood. 2006; 108:2485–2492. [PubMed: 1678097]

21. Tawara I, Sun Y, Liu C, Toubai T, Nieves E, et al. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. J Leukoc Biol. 2012; 91:667–675. [PubMed: 22262800]

22. Weston LE, Geczy AF, Briscoe H. Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD. Bone Marrow Transplant. 2006; 37:207–212. [PubMed: 16284610]

23. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998; 16:495–521. [PubMed: 9597139]

24. Wu Y, Bastian D, Schutt S, Nguyen H, Fu J, et al. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice. Biol Blood Marrow Transplant. 2015; 21:1195–1204. [PubMed: 25846718]

25. Wang H, Asavaroengchai W, Yap Y, Wang MG, Wang S, et al. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury. Blood. 2009; 113:3612–3619. [PubMed: 19211507]

26. Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WI. Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning. Biol Blood Marrow Transplant. 2000; 6:604–612. [PubMed: 11128810]

27. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of Interferon-gamma in GVHD and GVL. Cell Mol Immunol. 2005; 2:323–329. [PubMed: 16368058]

28. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant. 2003; 9:292–303. [PubMed: 12766879]

29. Pierini A, Strober W, Moffett C, Baker J, Nishikii H, et al. TNF-alpha priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood. 2016; 128:866–871. [PubMed: 27365424]

30. Leclerc M, Naserian S, Pilon C, Thiolat A, Martin GH, et al. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. Blood. 2016; 128:1651–1659. [PubMed: 27506541]

31. Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 1996; 15:50–73. [PubMed: 8739565]

32. Messmann JJ, Reisser T, Leithauser F, Lutz MB, Debatin KM. In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. Blood. 2015; 126:1138–1148. [PubMed: 26185131]

33. Korpelainen EI, Gamble JR, Vadas MA, Lopez AF. IL-3 receptor expression, regulation and function in cells of the vasculature. Immunol Cell Biol. 1996; 74:1–7. [PubMed: 8934648]

34. Valent P, Sillaber KC, Scherrer R, Geissler K, Kier P, et al. Detection of circulating endogenous interleukin-3 in extensive chronic graft-versus-host disease. Bone Marrow Transplant. 1992; 9:331–336. [PubMed: 1617317]
35. Atkinson K, Vos B, Kang-er Z, Guiffre A, Seymour R, et al. Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graft-versus-host disease and survival after murine haematopoietic stem cell transplantation. Cytokines Mol Ther. 1995; 1:47–55. [PubMed: 9384663]

36. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991; 77:1859–1870. [PubMed: 2018830]

37. Andrews AL, Holloway JW, Holgate ST, Davies DT. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol. 2006; 176:7456–7461. [PubMed: 16751391]

38. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, et al. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease. J Immunol. 1995; 154:2687–2696. [PubMed: 7876541]

39. Foley JE, Mariotti J, Ryan K, Eckhaus M, Fowler DH. Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transplant. 2008; 14:959–972. [PubMed: 18721759]

40. Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009; 21:1303–1309. [PubMed: 19819937]

41. Imoto S, Oomoto Y, Murata K, Das H, Murayama T, et al. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease. Int J Hematol. 2000; 72:92–97. [PubMed: 10979216]

42. Jordan WJ, Brookes PA, Szydlo RM, Goldman JM, Lechler RI, et al. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood. 2004; 103:717–724. [PubMed: 14512310]

43. Liu Y, Cai Y, Dai L, Chen G, Ma X, et al. The expression of Th17-associated cytokines in human acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013; 19:1421–1429. [PubMed: 23792271]

44. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009; 113:1365–1374. [PubMed: 18957685]

45. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27:485–517. [PubMed: 19132915]

46. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009; 113:945–952. [PubMed: 18931341]

47. van der Waart AB, van der Velden WJ, Blijlevens NM, Dolstra H. Targeting the IL17 pathway for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20:752–759. [PubMed: 24565991]

48. Zhao K, Ruan S, Yin L, Zhao D, Chen C, et al. Dynamic regulation of effector IFN-Î³-producing and IL-17-producing T cell subsets in the development of acute graft-versus-host disease. Mol Med Rep. 2016; 13:1395–1403. [PubMed: 26647759]

49. Hanash AM, Dudakov JA, Hua G, O’Connor MH, Young LF, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012; 37:339–350. [PubMed: 22921121]

50. Lindemans CA, Calafiore M, Mertelsmann AM, O’Connor MH, Dudakov JA, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature. 2015; 528:560–564. [PubMed: 26649819]

51. Konya V, Mjösberg J. Innate lymphoid cells in graft-versus-host disease. Am J Transplant. 2015; 15:2795–2801. [PubMed: 26228632]

52. Thompson JS, Hardin DL, Glass JF3, Dziba J3, Campion J4, et al. The Inflammatory Cytokine IL-21 is Expressed by Splenic Neutrophils in Response to Transplantation of Allogeneic Cells. J Immunol. 2016; 4:1–9. [PubMed: 27774526]

53. Wu X, Tan Y, Xing Q, Wang S. IL-21 accelerates xenogeneic graft-versus-host disease correlated with increased B-cell proliferation. Protein Cell. 2013; 4:863–871. [PubMed: 24214876]
54. Lim JY, Park MJ, Im KI, Kim N, Park HS, et al. Interleukin 21 blockade modulates activated T- and B-cell homeostasis via B-cell activating factor pathway-mediated inhibition in a murine model of acute graft-versus-host disease. Exp Hematol. 2015; 43:23–31. e21–22. [PubMed: 25246268]
55. Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016; 127:2144–2154. [PubMed: 26983850]
56. El-Asady R, Yuan R, Liu K, Wang D, Gress RE, et al. TGF-[beta]-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. J Exp Med. 2005; 201:1647–1657. [PubMed: 15897278]
57. Zhang XH, Zhou Y, Zhang JM, Zhou SY, Wang M, et al. IL-35 inhibits acute graft-versus-host disease in a mouse model. Int Immunopharmacol. 2015; 29:383–392. [PubMed: 26507167]
58. Bazdar DA, Kalinowska M, Panigrahi S, Sieg SF. Recycled IL-7 Can Be Delivered to Neighboring T Cells. J Immunol. 2015; 194:4698–4704. [PubMed: 25870237]
59. Politikos I, Kim HT, Nikiforow S, Li L, Brown J, et al. IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS One. 2015; 10:e0132564. [PubMed: 26177551]
60. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001; 97:14–32. [PubMed: 1133738]
61. Thiant S, Moutuou MM, Leboeuf D, Guimond M. Homeostatic cytokines in immune reconstitution and graft-versus-host disease. Cytokine. 2016; 82:24–32. [PubMed: 26795458]
62. Ahmed SS, Wang XN, Norden J, Pearce K, El-Gezawy E, et al. Identification and validation of biomarkers associated with acute and chronic graft versus host disease. Bone Marrow Transplant. 2015; 50:1563–1571. [PubMed: 26367225]
63. Koyama M, Cheong M, Markey KA, Gartlan KH, Kuns RD, et al. Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. The Journal of experimental medicine. 2015; 212:1303–1321. [PubMed: 26169940]
64. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015; 125:3183–3192. [PubMed: 25814531]
65. Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber FC, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med. 2013; 210:1899–1910. [PubMed: 23980097]
66. Lim JY, Lee YK, Lee SE, Ju JM, Park G, et al. Attenuation of Hepatic Graft-versus-host Disease in Allogeneic Recipients of MyD88-deficient Donor Bone Marrow. Immune Netw. 2015; 15:125–134. [PubMed: 26140044]
67. Shin HH, Baker J, Leveson-Gower DB, Smith AT, Sega EI, et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood. 2011; 118:2342–2350. [PubMed: 21734238]
68. Zhao D, Zhang C, Yi T, Lin CL, Todorov I, et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood. 2008; 112:2129–2138. [PubMed: 18550852]
69. Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, et al. Th17/Treg ratio in human graft-versus-host disease. Blood. 2010; 116:1165–1171. [PubMed: 20484086]
70. Forcade E, Kim HT, Cutler C, Wang K, Alho AC, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016; 127:2489–2497. [PubMed: 26944544]
71. Zhou V, Agle K, Chen X, Beres A, Komorowski R, et al. A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. J Clin Inv. 2016; 126:3541–3555.
72. Rosenkranz E, Metz CH, Maywald M, Hilgers RD, Weßels I, et al. Zinc supplementation induces regulatory T cells by inhibition of Sirt-1 deacetylase in mixed lymphocyte cultures. Mol Nutr Food Res. 2016; 60:661–671. [PubMed: 26614004]
74. Du W, Leigh ND, Bian G, O’Neill RE, Mei L, et al. Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. J Immunol. 2015; 195:4514–4523. [PubMed: 26392464]

75. Wang Y, Liang Y, Zhang Y, Wu D, Liu H. Bortezomib inhibits bone marrow-derived dendritic cells. Int J Clin Exp Pathol. 2015; 8:4857–4862. [PubMed: 26191178]

76. Long J, Chang L, Shen Y, Gao WH, Wu YN, et al. Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells. J Immunol. 2015; 195:1849–1857. [PubMed: 26179902]

77. Im KI, Kim N, Lim JY, Nam YS, Lee ES, et al. The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release. J Immunol. 2015; 194:5223–5232. [PubMed: 25911749]

78. Morin F, Kavian N, Marut W, Chereau C, Cerles O, et al. Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model. J Invest Dermatol. 2015; 135:2385–2393. [PubMed: 25938558]

79. Sun Y, Wang Y, Toubai T, Oravecz-Wilson K, Liu C, et al. BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 2015; 125:2724–2728. [PubMed: 25778533]

80. Wu Y, Heinrichs J, Bastian D, Fu J, Nguyen H, et al. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood. 2015; 126:1314–1323. [PubMed: 26138686]

81. Sun Y, Oravecz-Wilson K, Mathewson N, Wang Y, McEachin R, et al. Mature T cell responses are controlled by microRNA-142. J Clin Invest. 2015; 125:2825–2840. [PubMed: 26098216]

82. Chen S, Smith BA, Iype J, Prestipino A, Pfeifer D, et al. MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood. 2015; 126:103–112. [PubMed: 25972159]

83. Stickel N, Prinz G, Pfeifer D, Hasselblatt P, Schmitt-Graeff A, et al. MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GVHD. Blood. 2014; 124:2586–2595. [PubMed: 25205119]

84. Kim BS, Nishikii H, Baker J, Pierini A, Schneidawind D, et al. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. Blood. 2015; 126:546–557. [PubMed: 26063163]

85. Chopra M, Brandl A, Siegmund D, Mottok A, Schaefer V, et al. Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. Blood. 2015; 126:437–444. [PubMed: 26012567]

86. Jung JW, Han SJ, Song MK, Kim TI, Kim EK, et al. Tear Cytokines as Biomarkers for Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015; 21:2079–2085. [PubMed: 26303101]

87. Cocho L, Fernandez I, Calonge M, Martinez V, Gonzalez-Garcia MJ, et al. Gene Expression-Based Predictive Models of Graft Versus Host Disease-Associated Dry Eye. Invest Ophthalmol Vis Sci. 2015; 56:4570–4581. [PubMed: 26200497]

88. Hüber CM, Doisne JM, Colucci F. IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation. Eur J Immunol. 2015; 45:1727–1735. [PubMed: 25778912]
Figure 1. A graphical representation for the role of cytokines in GVHD pathogenesis. Following allogeneic hematopoietic cell transplantation, donor T cells recognize allo-antigens present on the host antigen presenting cells (APCs). As a result of T cell receptor (TCR) activation and co-stimulation, donors T cells activate, proliferate and expand in the presence of cytokines. The presence of various cytokines also influences the differentiation of naïve T cells into Th1, Th2, Treg and Th17 cells. Furthermore, T cells migrate to the target organs such as skin, liver and gut and release proinflammatory cytokines that lead to induction of GVHD.